Qvents

Qvents

Discussion forum for Pharma Quality events, Regulatory Actions

Warning letters, 483s, Recalls, Import Alerts, Audit observations

Novartis recall one lot of Sandimmune®

Sandimmune® Oral Solution (cyclosporine oral solution, USP), 100 mg/mL is indicated for the prophylaxis of

Abbot recall all batches of Digene Gel o

Abbot recalls all batches of Digene Gel of all flavours (Mint, Orange, Mix fruit flavours)

FDA removes REMS requirement for alosetr

USFDA has eliminated the REMS for Lotronex (alosetron hydrochloride) and approved generics. Alosetron hydrochloride is

USFDA announces funding opportunity for

USFDA has announced funding opportunity for FDA Orphan Products Clinical Trials Grant Program. The deadline

Marlex Pharmaceuticals, US, recall one l

Bottles of Digoxin Tablets, USP 0.125mg are incorrectly labelled and contain Digoxin Tablets USP, 0.25mg

Merck Animal Health (MSD) recalls three

Flunixin meglumine is a potent, non-narcotic, nonsteroidal, analgesic agent with anti-inflammatory and antipyretic activity. It

USFDA issues new draft guidance for Post

As per the GDUFA III commitment letter, USFDA has issued a draft guidance for facilities

Warning Letter to US Eye Drop Manufactur

The USFDA Warning letter to K. C. Pharmaceuticals issued in August 2023, following inspection at

Alembic recall 82400 bottles of Tobramyc

In a Class III recall in US, Alembic recalled 82400 bottles of Tobramycin 0.3%, Ophthalmic

Aurobindo recalls (Class II) Rufinamide

Rufinamide tablets are indicated for adjunctive treatment of seizures associated with Lennox-Gastaut Syndrome (LGS). Aurobindo